# Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

> **NCT03464734** · PHASE2 · COMPLETED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 70 (actual)

## Conditions studied

- Metastatic Urothelial Carcinoma

## Interventions

- **DRUG:** Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel

## Key facts

- **NCT ID:** NCT03464734
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-16
- **Primary completion:** 2020-01-21
- **Final completion:** 2020-01-21
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2022-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03464734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03464734, "Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03464734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*